Track topics on Twitter Track topics that are important to you
REDMOND, Wash., Aug. 8, 2017 /PRNewswire/ -- VerAvanti, a developer of a new class of scientifically-advanced solutions to help physicians find answers to treat strokes and heart attacks that often strike without warning, is leveraging deep industry ties from its founding team, to build a highly experienced and industry-recognizable board, clinical advisors, and leadership team to strategically guide the company as it readies for a planned 2018 market launch, pending FDA 510(k) premarket clearance.
VerAvanti Founder and CEO, Gerald McMorrow stated, "A key advantage that VerAvanti President Russell Garrison and I bring to this venture is years of entrenched industry experience and connections in the medical device market that we plan to leverage. We are hand-picking some of the industry's brightest leaders that include a Board and Clinical Advisory Team who can provide critical counsel and experience to actively bolster our expanding leadership team's go-to-market efforts."
VerAvanti President Russell Garrison elaborated on the importance of this early team, "VerAvanti is marshalling the human capital and resources needed to leverage the millions of dollars and decade of industry research already devoted to the development of this technology, to create a viable medical device so that physicians and the healthcare systems they work with have the potential to more proactively diagnose and treat individuals at-risk for stroke and cardiovascular events." Garrison added, "When this is achieved, VerAvanti, its shareholders, and employees will fulfill a shared vision of saving more patient lives."
In addition to McMorrow and Garrison, the VerAvanti Board includes Seattle medical device industry pioneer and luminary, Dr. David C. Auth, Ph.D., P.E., who currently serves as the Chairman and Chief Executive Officer of CoAptus Medical Corporation, and earlier founded Heart Technology, Inc., now a division of Boston Scientific Corp. In addition to being an entrepreneur and businessman, Auth has been an Affiliate Professor of Bioengineering at the University of Washington since 1985 and is a physicist, renowned scientist, and inventor of several commercially successful products in the medical device field including the Rotablator, and is a co-inventor of the NovaSure System.
The VerAvanti Clinical Advisory team includes four highly respected physicians who each bring an unprecedented depth of related industry experience and research knowledge to the company.
Early strategic hires to the VerAvanti leadership team include:
VerAvanti is actively recruiting engineers and quality professionals, as it readies the company for its 2018 market launch.
About VerAvantiFounded in 2013, privately-held VerAvanti is using advanced science and automation to commercialize the world's first Scanning Fiber Endoscope (SFE), to help physicians close treatment gaps and proactively identify interventions for the 200,000 individuals (U.S.) who suffer ischemic strokes due to an unknown cause1. Protected by more than 30 patents licensed by VerAvanti, the SFE is a micro-imaging catheter equipped with an extreme depth of focus camera that provides physicians a previously unseen surgical view into hidden intravascular anatomy, enabling more proactive diagnosis and treatment of individuals at-risk for stroke and cardiovascular events. Visit VerAvanti to learn more and review scientific papers and SFE images.
Photos available upon request.
Media Inquiries: Cheryl Isen, Isen and Company
email@example.com or (425) 233-9032
View original content with multimedia:http://www.prnewswire.com/news-releases/veravanti-mobilizes-notable-industry-advisors-and-expands-go-to-market-leadership-team-300500958.html
SOURCE VerAvantiNEXT ARTICLE
Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...
The role of medical devices in healthcare is essential. The diversity and innovativeness of this sector contribute significantly to enhance the quality and efficacy of healthcare. Covering a wide range of products, from simple bandages to the...